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Background:  An early invasive strategy after fibrinolysis for ST elevation myocardial infarction (STEMI) improves outcomes; the relative efficacy 
and safety of enoxaparin compared with unfractionated heparin (UFH) as part of this pharmacoinvasive approach are unknown.
Methods:  In the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI), 
STEMI patients received fibrinolysis and were randomized to standard treatment or to immediate transfer for coronary angiography. Enoxaparin or 
UFH was given at the discretion of the treating physician, but enoxaparin was restricted to age <75 years; this analysis is restricted to patients <75 
years.
Results:  The primary end point was the composite of 30-day death, reinfarction, recurrent ischemia, new or worsening heart failure, or cardiogenic 
shock. The efficacy and safety endpoints (adjusted logistic regression models) are shown in the Table; propensity score results were similar. There 
were no significant interactions between treatment groups (standard vs. pharmacoinvasive), type of anticoagulant, and outcome.
Conclusions:  Among high-risk STEMI patients treated with fibrinolysis and undergoing transfer for cardiac catheterization, enoxaparin was 
associated with similar efficacy and severe bleeding rates compared to UFH; however, there was more access site and mild bleeding with 
enoxaparin.
Efficacy and Safety Outcomes 
Outcome
UFH
(n=448)
Enoxaparin (n=498)
Adjusted OR
(Enoxaparin vs. UFH)
P value
Primary endpoint (30 days) 11.6% 11.9% 0.93 (0.59-1.46) 0.74
Re-infarction (30 days) 4.7% 4.4% 0.83 (0.42-1.64) 0.59
Death (30 days) 2.5% 2.4% 0.78 (0.23-2.70) 0.70
Death (1 year) 4.1% 3.7% 0.84 (0.32-2.18) 0.72
Severe bleeding (In-hospital) 1.3% 1.4% 1.28 (0.40-4.12) 0.67
Mild bleeding (In-hospital) 7.8% 12.1% 1.60 (1.03-2.52) 0.04
Access site bleeding (In-hospital) 2.9% 5% 2.07 (1.03-4.19) 0.04
